certolizumab pegol

Home » Classic Medicine » Pharmacology » certolizumab pegol
certolizumab pegol2016-12-25T03:04:02+00:00

certolizumab pegol


Other names Cimzia, CPD870

A humanised monoclonal antibody that inhibits tumour-necrosis factor-alpha–TNF-alpha, which is FDA-approved for managing Crohn’s disease* and rheumatoid arthritis.

*Per PRECISE-1 and PRECISE-2 trials Per RAPID-1 and RAPID-2 trials

Adverse effects Heart failure, dizziness, paraesthesias of extremities, allergic reactions, immune suppression, lupus-like symptoms, increased risk of infections and lymphomas

References http://en.wikipedia.org/wiki/Certolizumab_pegol
Product literature, UCB, Inc. 

Leave A Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.